Find Your Fit – Theranostics
These resources are to be used for the field of theranostics. It is a quickly advancing field and textbooks often don’t show the whole picture. These are to help expand the discussion and research for new and emerging tracers for therapy.
Innovative Radiopharmaceuticals in Oncology and Neurology
The aim of this Research Topic was to assemble a series of articles describing basic, preclinical and clinical research studies on radiopharmaceuticals and nuclear medicine. The articles were written by attendees of the third Nuclear Technologies for Health Symposium (NTHS, 10th-11th March 2015, Nantes, Frances) under the auspices of the IRON LabEx (Innovative Radiopharmaceuticals for Oncology and Neurology Laboratory of Excellence). This French network, gathering approximately 160 scientists from 12 academic research teams (Funded by “investissements d’Avenir”), fosters transdisciplinary projects between teams with expertise in chemistry, radiochemistry, radiopharmacy, formulation, biology, nuclear medicine and medical physics. The 12 articles within this resulting eBook present a series of comprehensive reviews and original research papers on multimodality imaging and targeted radionuclide therapy; illustrating the different facets of studies currently conducted in these domains.
2 https://directory.doabooks.org/handle/20.500.12854/128809
PET/CT Imaging in Oncology: Clinical Updates and Perspectives
This reprint focuses on the most recent advances in PET/CT imaging within the field of oncology. These innovations include studies on novel or experimental tracers, such as [18F]FES for the imaging of advanced breast cancer and [68Ga]Ga-Nitroimidazole for visualizing hypoxic tumour components; research on new radiopharmaceuticals represents, in fact, one the most important study fields of PET research. Advanced image analysis, such as radiomics, is also featured in this reprint; this method has been applied to both traditional nuclear medicine clinical issues, such as thyroid nodules, as well as in the setting of new therapeutic approaches, such as CAR-T cell therapy. Finally, the theranostic implications of PET radiotracers and the diagnostic processes of rare tumours are explored in this reprint.
https://mdpi.com/books/pdfview/book/8276
- Targeted Therapy for Metastatic Prostate Cancer with Radionuclides
Progression to androgen-independent status is the main cause of death in patients with metastatic prostate cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly upregulated in prostate cancer. Therefore, it is an appro‐ priate target for diagnosis and therapy of prostate cancer and its metastases. There is growing knowledge about promising response and low toxicity profile of radioligand therapy of metastatic castration-resistant prostate cancer using Lutetium-177-labeled PSMA ligands. For patients with only bone metastases, there are different radionu‐ clides which have been used for decades. In this chapter, different methods of targeted radionuclide therapy of metastatic prostate cancer are described.
https://openresearchlibrary.org/viewer/58a2df61-e90e-407c-afac-465f52e9d1bf/2
Tweet
Example for "Find Your Fit – Theranostics":
n/a
Leave a Reply